Glomerulonephritis
MONDO:0002462A renal disorder characterized by damage in the glomeruli. It may be acute or chronic, focal or diffuse, and it may lead to renal failure. Causes include autoimmune disorders, infections, diabetes, and malignancies.
Also known as: glomerular nephritis, glomerulonephritis, glomerulonephritis (disease), nephritis of renal glomerulus, renal glomerulus nephritis, bright's disease
457 clinical trials for this condition and its sub-types, 33 tagged with Glomerulonephritis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Glomerulonephritis
-
Lupus nephritis 140 trials
-
IgA glomerulonephritis 123 trials
-
Granulomatosis with polyangiitis 95 trials · 115 incl. sub-types
1 sub-type
-
Membranous glomerulonephritis 69 trials · 77 incl. sub-types
1 sub-type
- Idiopathic membranous glomerulonephritis 50 trials
-
Lipoid nephrosis 32 trials
-
Primary membranoproliferative glomerulonephritis 0 trials · 26 incl. sub-types
3 sub-types
- Complement 3 glomerulopathy 23 trials · 24 incl. sub-types Sub-types →
- Immunoglobulin-mediated membranoproliferative glomerulonephritis 12 trials
- Membranoproliferative glomerulonephritis, X-linked 0 trials
-
Membranoproliferative glomerulonephritis 11 trials
-
Pauci-immune glomerulonephritis 1 trial · 5 incl. sub-types
2 sub-types
-
Rapidly progressive glomerulonephritis 3 trials · 4 incl. sub-types
1 sub-type
-
Proliferative glomerulonephritis 1 trial · 2 incl. sub-types
1 sub-type
- Acute proliferative glomerulonephritis 0 trials · 1 incl. sub-types Sub-types →
-
Immunotactoid glomerulopathy 1 trial
-
Autoimmune glomerulonephritis 0 trials
-
Diffuse glomerulonephritis 0 trials
1 sub-type
- Acute diffuse glomerulonephritis 0 trials
-
Exudative glomerulonephritis 0 trials
-
Focal embolic glomerulonephritis 0 trials
-
Immune-complex glomerulonephritis 0 trials
-
Subacute glomerulonephritis 0 trials
Most studied deeper sub-types
-
Could CAR-T cells tame tough lupus kidney disease?
Disease control Stopped earlyThis early-phase trial is testing a new treatment called KYV-101, which uses a patient's own modified immune cells (CAR-T cells) to target and destroy faulty B cells that drive lupus kidney inflammation. The study involves 6 adults with lupus nephritis that hasn't responded to st…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental CAR-T therapy takes on Hard-to-Treat lupus nephritis
Disease control Stopped earlyThis early-phase trial is testing a personalized cell therapy called KYV-101 for people with lupus nephritis that hasn't responded to standard treatments. The therapy uses a patient's own immune cells, modified to target and destroy faulty B cells that drive the disease. Only 2 p…
Phase 1/2 • Sponsor: Kyverna Therapeutics • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Experimental drug ravulizumab tested for kidney inflammation
Disease control Stopped earlyThis Phase 2 study tested the drug ravulizumab (Ultomiris) in 123 adults with lupus nephritis or IgA nephropathy, two conditions that cause kidney inflammation. Participants received either ravulizumab or a placebo alongside standard care. The study aimed to see if the drug could…
Phase 2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC